Gizem Calibasi-Kocal

Prof. Dr. Gizem Calibasi-Kocal

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Cell
Verified
Journal Article
Closed access
CCChia-Wei Cheng
Chia-Wei Cheng
MBMoshe Biton
Moshe Biton
AHAdam L. Haber
Adam L. Haber
NGNuray Gunduz
Nuray Gunduz
GEGeorge Eng
George Eng
ÖYÖmer H. Yilmaz
Ömer H. Yilmaz

21 August 2024 in Nature
Verified
Journal Article
Closed access
PDF file
SIShinya Imada
Shinya Imada
SKSaleh Khawaled
Saleh Khawaled
HSHeaji Shin
Heaji Shin
SMSven W. Meckelmann
Sven W. Meckelmann
CWCharles A. Whittaker
Charles A. Whittaker
ÖYÖmer H. Yilmaz
Ömer H. Yilmaz

1 January 2021 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Closed access
Gizem Calibasi-KocalGizem Calibasi-Kocal
Gizem Calibasi-Kocal
OMOmid Mashinchian
Omid Mashinchian
YBYasemin Basbinar
Yasemin Basbinar
EEEnder Ellidokuz
Ender Ellidokuz
CCChia-Wei Cheng
Chia-Wei Cheng
ÖYÖmer H. Yilmaz
Ömer H. Yilmaz

2 December 2016 in Scientific Reports
Verified
Journal Article
Open access
Gizem Calibasi-KocalGizem Calibasi-Kocal
Gizem Calibasi-Kocal
SGSinan Güven
Sinan Güven
KFKira Foygel
Kira Foygel
AGAaron Goldman
Aaron Goldman
PCPu Chen
Pu Chen
UDUtkan Demirci
Utkan Demirci
Cancer microenvironment is a remarkably heterogeneous composition of cellular and non-cellular components, regulated by both external and intrinsic physical and chemical stimuli. Physical alterations driven by increased proliferation of neoplastic cells and angiogenesis in the cancer microenvironment result in the exposure of the cancer cells to elevated levels of flow-based shear stress. We developed a dynamic microfluidic cell culture platform utilizing eshopagael cancer cells as model cells to investigate the phenotypic changes of cancer cells upon exposure to fluid shear stress. We report the epithelial to hybrid epithelial/mesenchymal transition as a result of decreasing E-Cadherin and increasing N-Cadherin and vimentin expressions, higher clonogenicity and ALDH positive expression of cancer cells cultured in a dynamic microfluidic chip under laminar flow compared to the static culture condition. We also sought regulation of chemotherapeutics in cancer microenvironment towards phenotypic control of cancer cells. Such in vitro microfluidic system could potentially be used to monitor how the interstitial fluid dynamics affect cancer microenvironment and plasticity on a simple, highly controllable and inexpensive bioengineered platform.

1 July 2019
Verified
Journal Article
Closed access
Gizem Calibasi-KocalGizem Calibasi-Kocal
Gizem Calibasi-Kocal
APAhu Pakdemirli
Ahu Pakdemirli
SBSerdar Bayrak
Serdar Bayrak
NONazli Mert Ozupek
Nazli Mert Ozupek
TSTolga Sever
Tolga Sever
TYTurkan Yigitbasi
Turkan Yigitbasi

30 October 2025 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
PDF file
AAAdile Buse Andac-Aktas
Adile Buse Andac-Aktas
Gizem Calibasi-KocalGizem Calibasi-Kocal
Gizem Calibasi-Kocal
Colorectal cancer (CRC) remains one of the most lethal malignancies worldwide, with outcomes shaped not only by genetic alterations but also by the complexity of the tumor microenvironment (TME). The TME encompasses stromal and endothelial cells, extracellular matrix components, gut microbiota, and a diverse array of immune cells that dynamically interact to influence tumor initiation, progression, and therapeutic response. This review delineates the immunological landscape of CRC, highlighting the dual functions of innate immune cells—including tumor-associated macrophages, natural killer cells, dendritic cells, neutrophils, and mast cells—and adaptive immune players such as cytotoxic T lymphocytes, helper T-cell subsets, and B/plasma cells. These cellular interactions contribute to the heterogeneity between immunologically “hot” microsatellite instability-high (MSI-H) tumors, which are highly responsive to immunotherapy, and “cold” microsatellite-stable (MSS) tumors, which remain resistant. Key mechanisms of immune evasion, such as cancer immunoediting, checkpoint signaling, and exosome-mediated communication, are examined alongside prognostic tools like the Immunoscore that serve as biomarkers of immune infiltration. Emerging immunotherapeutic strategies, including checkpoint blockade, macrophage reprogramming, natural killer cell agonists, and microbiome modulation, are discussed with emphasis on both their promise and limitations in CRC management. By integrating current insights into immune–tumor interactions, the review underscores opportunities for developing personalized, TME-targeted interventions to improve CRC outcomes.